237 related articles for article (PubMed ID: 35163019)
21. Isocitrate dehydrogenase mutations in chondrosarcoma: the crossroads between cellular metabolism and oncogenesis.
Azzi G; Velez M; Mathias-Machado MC
Curr Opin Oncol; 2014 Jul; 26(4):403-7. PubMed ID: 24867810
[TBL] [Abstract][Full Text] [Related]
22. An orthotopic mouse model for chondrosarcoma of bone provides an in vivo tool for drug testing.
van Oosterwijk JG; Plass JR; Meijer D; Que I; Karperien M; Bovée JV
Virchows Arch; 2015 Jan; 466(1):101-9. PubMed ID: 25331842
[TBL] [Abstract][Full Text] [Related]
23. Clinical activity of mTOR inhibition in combination with cyclophosphamide in the treatment of recurrent unresectable chondrosarcomas.
Bernstein-Molho R; Kollender Y; Issakov J; Bickels J; Dadia S; Flusser G; Meller I; Sagi-Eisenberg R; Merimsky O
Cancer Chemother Pharmacol; 2012 Dec; 70(6):855-60. PubMed ID: 23053256
[TBL] [Abstract][Full Text] [Related]
24. A novel benzofuran derivative, ACDB, induces apoptosis of human chondrosarcoma cells through mitochondrial dysfunction and endoplasmic reticulum stress.
Su CM; Chen CY; Lu T; Sun Y; Li W; Huang YL; Tsai CH; Chang CS; Tang CH
Oncotarget; 2016 Dec; 7(50):83530-83543. PubMed ID: 27835579
[TBL] [Abstract][Full Text] [Related]
25. Unique mutation portraits and frequent COL2A1 gene alteration in chondrosarcoma.
Totoki Y; Yoshida A; Hosoda F; Nakamura H; Hama N; Ogura K; Yoshida A; Fujiwara T; Arai Y; Toguchida J; Tsuda H; Miyano S; Kawai A; Shibata T
Genome Res; 2014 Sep; 24(9):1411-20. PubMed ID: 25024164
[TBL] [Abstract][Full Text] [Related]
26. Mutant IDH regulates glycogen metabolism from early cartilage development to malignant chondrosarcoma formation.
Pathmanapan S; Poon R; De Renshaw TB; Nadesan P; Nakagawa M; Seesankar GA; Ho Loe AK; Zhang HH; Guinovart JJ; Duran J; Newgard CB; Wunder JS; Alman BA
Cell Rep; 2023 Jun; 42(6):112578. PubMed ID: 37267108
[TBL] [Abstract][Full Text] [Related]
27. Clinico-Genomic Profiling of Conventional and Dedifferentiated Chondrosarcomas Reveals TP53 Mutation to Be Associated with Worse Outcomes.
Denu RA; Yang RK; Lazar AJ; Patel SS; Lewis VO; Roszik J; Livingston JA; Wang WL; Shaw KR; Ratan R; Zarzour MA; Bird J; Raza S; Akdemir KC; Rodon Ahnert J; Subbiah V; Patel S; Conley AP
Clin Cancer Res; 2023 Dec; 29(23):4844-4852. PubMed ID: 37747813
[TBL] [Abstract][Full Text] [Related]
28. Intracellular cholesterol biosynthesis in enchondroma and chondrosarcoma.
Zhang H; Wei Q; Tsushima H; Puviindran V; Tang YJ; Pathmanapan S; Poon R; Ramu E; Al-Jazrawe M; Wunder J; Alman BA
JCI Insight; 2019 Apr; 5(11):. PubMed ID: 31039139
[TBL] [Abstract][Full Text] [Related]
29. Periosteal chondrosarcoma: a histopathological and molecular analysis of a rare chondrosarcoma subtype.
Cleven AH; Zwartkruis E; Hogendoorn PC; Kroon HM; Briaire-de Bruijn I; Bovée JV
Histopathology; 2015 Oct; 67(4):483-90. PubMed ID: 25648524
[TBL] [Abstract][Full Text] [Related]
30. Recombinant human PDCD5 sensitizes chondrosarcomas to cisplatin chemotherapy in vitro and in vivo.
Chen C; Zhou H; Xu L; Xu D; Wang Y; Zhang Y; Liu X; Liu Z; Ma D; Ma Q; Chen Y
Apoptosis; 2010 Jul; 15(7):805-13. PubMed ID: 20349137
[TBL] [Abstract][Full Text] [Related]
31. Biology and Management of High-Grade Chondrosarcoma: An Update on Targets and Treatment Options.
Tlemsani C; Larousserie F; De Percin S; Audard V; Hadjadj D; Chen J; Biau D; Anract P; Terris B; Goldwasser F; Pasmant E; Boudou-Rouquette P
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674874
[TBL] [Abstract][Full Text] [Related]
32. IDH1 mutations are not found in cartilaginous tumours other than central and periosteal chondrosarcomas and enchondromas.
Damato S; Alorjani M; Bonar F; McCarthy SW; Cannon SR; O'Donnell P; Tirabosco R; Amary MF; Flanagan AM
Histopathology; 2012 Jan; 60(2):363-5. PubMed ID: 22074484
[No Abstract] [Full Text] [Related]
33. Chemotherapy and P-glycoprotein expression in chondrosarcoma.
Terek RM; Schwartz GK; Devaney K; Glantz L; Mak S; Healey JH; Albino AP
J Orthop Res; 1998 Sep; 16(5):585-90. PubMed ID: 9820282
[TBL] [Abstract][Full Text] [Related]
34. The oncogene LRF is a survival factor in chondrosarcoma and contributes to tumor malignancy and drug resistance.
Kumari R; Li H; Haudenschild DR; Fierro F; Carlson CS; Overn P; Gupta L; Gupta K; Nolta J; Yik JH; Di Cesare PE
Carcinogenesis; 2012 Nov; 33(11):2076-83. PubMed ID: 22847180
[TBL] [Abstract][Full Text] [Related]
35. Trichodermin induces cell apoptosis through mitochondrial dysfunction and endoplasmic reticulum stress in human chondrosarcoma cells.
Su CM; Wang SW; Lee TH; Tzeng WP; Hsiao CJ; Liu SC; Tang CH
Toxicol Appl Pharmacol; 2013 Oct; 272(2):335-44. PubMed ID: 23806212
[TBL] [Abstract][Full Text] [Related]
36. Structure-activity relationship study of hypoxia-activated prodrugs for proteoglycan-targeted chemotherapy in chondrosarcoma.
Ghedira D; Voissière A; Peyrode C; Kraiem J; Gerard Y; Maubert E; Vivier M; Miot-Noirault E; Chezal JM; Farhat F; Weber V
Eur J Med Chem; 2018 Oct; 158():51-67. PubMed ID: 30199705
[TBL] [Abstract][Full Text] [Related]
37. Novel treatment targets in sarcoma: more than just the GIST.
Shoushtari AN; Van Tine BA; Schwartz GK
Am Soc Clin Oncol Educ Book; 2014; ():e488-95. PubMed ID: 24857144
[TBL] [Abstract][Full Text] [Related]
38. SF2523 inhibits human chondrosarcoma cell growth in vitro and in vivo.
Zhu JX; Xiao JR
Biochem Biophys Res Commun; 2019 Apr; 511(3):559-565. PubMed ID: 30824188
[TBL] [Abstract][Full Text] [Related]
39. EphA2 Expression in Bone Sarcomas: Bioinformatic Analyses and Preclinical Characterization in Patient-Derived Models of Osteosarcoma, Ewing's Sarcoma and Chondrosarcoma.
Giordano G; Merlini A; Ferrero G; Mesiano G; Fiorino E; Brusco S; Centomo ML; Leuci V; D'Ambrosio L; Aglietta M; Sangiolo D; Grignani G; Pignochino Y
Cells; 2021 Oct; 10(11):. PubMed ID: 34831119
[TBL] [Abstract][Full Text] [Related]
40. [Inflammation as molecular target in chondrosarcoma].
Kalinski T
Pathologe; 2014 Nov; 35 Suppl 2():249-53. PubMed ID: 25394974
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
